Prof Nat Lenzo

  • Nuclear Medicine and Internal Medicine Physician
  • Spoken languages English, Italian


Publications and affiliations

  1. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer. Asokendaran ME, Meyrick DP, Skelly LA, Lenzo NP, Henderson A. World J Nucl Med. 2019 Jul-Sep;18(3):232-237. doi: 10.4103/wjnm.WJNM_59_18. PMID: 31516365 Free PMC article.
  2. Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. Gallyamov M, Meyrick D, Barley J, Lenzo N. Clin Kidney J. 2019 Aug 14;13(6):1049-1055. doi: 10.1093/ckj/sfz101. eCollection 2020 Dec. PMID: 33391748 Free PMC article.
  3. 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29. PMID: 31069008 Free PMC article.
  4. Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Cancer Biother Radiopharm. 2018 Sep;33(7):274-281. doi: 10.1089/cbr.2017.2403. Epub 2018 Jul 10. PMID: 29989440
  5. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Lenzo NP, Meyrick D, Turner JH. Diagnostics (Basel). 2018 Feb 11;8(1):16. doi: 10.3390/diagnostics8010016. PMID: 29439481 Free PMC article. Review.
  6. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A. Nucl Med Commun. 2017 Nov;38(11):956-963. doi: 10.1097/MNM.0000000000000738. PMID: 28922335